Ashish Pemawat: Is the 4.5-Hour Thrombolysis Window Becoming Less Relevant?
Ashish Pemawat, Associate Director of Institute of Neurosciences, shared on LinkedIn about a recent article by Ahmet Günkan et al, published in Stroke, adding:
”Is the 4.5-hour thrombolysis window becoming less relevant?
A recent meta-analysis published in Stroke (2025) pooled data from 8 randomized controlled trials involving 1,742 patients with acute ischemic stroke treated beyond the conventional 4.5-hour window.
Intravenous thrombolysis increased the odds of:
- Excellent functional outcome (mRS 0–1): OR 1.43
- Functional independence (mRS 0–2): OR 1.36
Additional benefits included higher rates of recanalization, reperfusion, and early neurological improvement.
As expected, symptomatic intracerebral hemorrhage was more frequent (OR 4.25), but importantly, there was no statistically significant increase in 90-day mortality.
The key message is clear: patient selection matters more than the clock.
Advanced imaging techniques—particularly perfusion imaging and DWI-FLAIR mismatch—can identify salvageable brain tissue and safely expand access to thrombolysis for selected patients presenting well beyond 4.5 hours or with wake-up stroke.
As stroke care continues to evolve, the paradigm is increasingly shifting from a rigid time-window approach toward a tissue-window approach, allowing more patients to benefit from reperfusion therapy.”
Title: Thrombolysis for Ischemic Stroke Beyond the 4.5-Hour Window: A Meta-Analysis of Randomized Clinical Trials
Authors: Ahmet Günkan, Marcio Yuri Ferreira, Marina Vilardo, Luca Scarcia, Jhon E. Bocanegra-Becerra, Leonardo Januario Campos Cardoso, Luis F. Fabrini Paleare, Gustavo de Oliveira Almeida, Gabriel Semione, Christian Ferreira, Gabriele Ciccio, Adnan Mujanovic, Pascal Jabbour, Yafell Serulle, Thanh N. Nguyen, Jean-Claude Baron

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 18, 2026, 15:49Heghine Khachatryan: ISTH 2026 – Final Day Highlights
-
Jul 18, 2026, 15:40Marc Carrier: New ISTH 2026 Data May Simplify DVT Evaluation During Pregnancy
-
Jul 18, 2026, 15:38Hermine Sayiyan: Dreams Do Come True – Often When We Least Expect Them
-
Jul 18, 2026, 15:31Alyaa Al-Mughairy: Presenting Real-World Emicizumab Data at the ISTH 2026 Middle East Summit
-
Jul 18, 2026, 15:25Rim Diab: Presenting Protein S Research as a Rebalancing Strategy at ISTH 2026
-
Jul 18, 2026, 15:22Owen McCarty: Honored to Speak at the 1st Mediterranean Platelet Symposium
-
Jul 18, 2026, 15:18Strengthening Regional Learning for Hemophilia and Sickle Cell Disease Care – Novo Nordisk
-
Jul 18, 2026, 14:54Fabien Mselati: Reflecting on 25 Years of Hemophilia Progress
-
Jul 18, 2026, 14:50Nikola Pantic: Grateful for the People Who Made ISTH 2026 Special